Urgent Alert: Safety Concerns Surrounding Meftal Spas – The Dangers of Mefenamic Acid Revealed

WhatsApp D. Pharma Group Join Now
Telegram D. Pharma Group Join Now
Telegram Group Latest Pharma Jobs Join Now
Telegram B. Pharma Group Join Now
Telegram Medicine Update Group Join Now
WhatsApp B. Pharma/ GPAT Channel Join Now

If you rely on Meftal Spas to alleviate pain, menstrual cramps, or manage rheumatoid arthritis, this news is of paramount importance. The Indian Pharmacopoeia Commission (IPC) has issued a critical drug safety alert, sounding the alarm on Meftal’s active ingredient, mefenamic acid. The alert underscores potential adverse reactions that could lead to a severe condition known as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome.

Meftal Spas

Understanding DRESS Syndrome:
1. DRESS syndrome, an acronym for Drug Reaction with Eosinophilia and Systemic Symptoms, is a severe and life-threatening hypersensitivity reaction triggered by certain medications.
2. Key features of DRESS syndrome include a widespread itchy rash, high fever, lymph node swelling, and inflammation of internal organs such as the liver, lungs, and heart.
3. An increase in eosinophils, a type of white blood cell, is a common characteristic of DRESS syndrome.

Alert from the Indian Pharmacopoeia Commission:
1. The IPC’s drug safety alert emphasizes the potential risks associated with the use of mefenamic acid in Meftal, urging healthcare professionals and consumers to be vigilant.
2. Closely monitor and promptly report any adverse drug reactions (ADRs) linked to Meftal.
3. The significance of reporting adverse reactions is underlined, emphasizing the role of the national coordination center of the Pharmacovigilance Programme of India (PvPI).

Government’s Advisory for Reporting:
1. Healthcare professionals and consumers are advised to report any adverse reactions promptly.
2. The advisory specifies channels for reporting, including the IPC website (www.ipc.gov.in), the Android mobile app ADR PvPI, and the PvPI Helpline Number (1800-180-3024).
3. Highlighting the collaborative effort needed to ensure drug safety, the government urges individuals to contribute to pharmacovigilance by reporting potential risks.

In the wake of the IPC’s alert, it is imperative for Meftal users and healthcare professionals to stay informed about the potential dangers associated with mefenamic acid. Vigilance, prompt reporting, and active participation in pharmacovigilance efforts are crucial to ensuring the safety of individuals relying on Meftal for pain relief and managing various conditions. Stay informed, stay safe.

<<<<<<<<<<<<<MORE NEWS>>>>>>>>>>>>>>>>

Empowering Ayurveda: CCRAS Launches ‘Ayurveda Gyan Naipunya Initiative’ (AGNI) to Elevate Evidence-Based Practices  Click  Here
CDSCO Reveals 5.5% of Drug Samples Not Meeting Standards in October 2023  Click  Here
The National Pharmacy Commission Bill 2023: A Closer Look at Education vs. Profession  Click  Here
Generic Aadhar Expands Its Noble Mission: Adds 111 New Franchise Outlets on Diwali  Click  Here
Delhi High Court Grants Eight Weeks for Central Government to Frame Policy on Online Sale of Drugs  Click  Here
Revolutionizing Pharma Safety: Proposed Revised Schedule M Guidelines to Enhance Drug Recall and Pharmacovigilance  Click  Here
Battle for Pharmacy Autonomy: AIOCD President Vigorously Opposes National Pharmacy Commission Proposal  Click  Here
Pharmacy Act Transition: Existing Educational Standards Continue Until New Benchmarks Set  Click  Here
NIPER PhD Scholars Revised Fellowship approved by Department of Pharmaceuticals  Click  Here
Redwing & Samridh Launches Groundbreaking Drone Network for Healthcare Delivery in Odisha’s Rayagada District  Click  Here
Unlocking the Sleep-Health Connection: Chronic Sleep Deficiency and Increased Insulin Resistance in Women, Especially Postmenopausal  Click  Here
National Pharmacy Commission Bill Introduces Pharmacy Advisory Council for Enhanced Regulation  Click  Here
Health Ministry Unveils Draft National Pharmacy Commission Bill 2023 – What You Need to Know Click  Here
The NPPA Sets a Price Cap on Nine Planned Formulations, one of which is a Medication for Brain Cancer Click  Here


<<<<<<<<<<<<<JOIN US>>>>>>>>>>>>>>>>

Subscribe our PHARMACY INDIA Youtube Channel for more Pharma Updates Click Here
Follow us on Instagram Click Here
Download PHARMACY INDIA MOBILE APP from Google Play Store  Click Here
Follow us on LinkedIn Click Here


Please enter your comment!
Please enter your name here